Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?

  • Hajira Ilyas
  • N. George Mikhaeel
  • Joel T. Dunn
  • Fareen Rahman
  • Henrik Möller
  • Daniel Smith
  • Sally F. BarringtonEmail author
Letter to the Editor

Dear Editor,

We thank the authors of this letter [1] written in response to our publication [2] for their interest and for engaging in the discussion about this important topic. Dr. Cottereau et al. [1] reiterate the key message from our publication that metabolic tumour volume (MTV) is a strong predictor of prognosis irrespective of the method; however, cut-offs used to divide patients into high and low risk groups by MTV are highly dependent on the patient population and the method used.

The authors indicate that their objective was to discuss the strengths and weaknesses of each segmentation method, which was the purpose of our study. However, they do not conclude that there is an optimal method yet, and indeed the letter’s title seems to suggest that there is not one. We concur that all methods have strengths and limitations and estimate prognosis well, but it is important to reiterate that the widespread adoption of MTV into routine practice will rely on two main factors; the ease...


Compliance with ethical standards

Ethical approval

Patient data were extracted from case records and reviewed only by members of the responsible clinical team, in compliance with the UK Data Protection Act; consequently, specific Research Ethics Approval and individual patient consent were not required. Professor Barrington acknowledges support from the National Institute of Health Research (NIHR) [RP-2-16-07-001]. King’s College London and UCL Comprehensive Cancer Imaging Centre is funded by the CRUK and EPSRC, in association with the MRC and Department of Health (England).The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. She has received research funding from Hermes Medical Solutions.


  1. 1.
    Cottereau AS, Buvat I, Kanoun S, Versari A, Casasnovas O, Chauvie S, et al. Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma? Eur J Nucl Med Mol Imaging. 2018;45(8):1463–4.CrossRefGoogle Scholar
  2. 2.
    Ilyas H, Mikhaeel NG, Dunn JT, Rahman F, Møller H, Smith D, Barrington SF. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142–54.CrossRefGoogle Scholar
  3. 3.
    Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella A, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Fingerle-Rowson G, Knapp A, Mattiello F, Nielsen T, Sellam G, Sahin D, Vitolo U, Trněný M. Baseline PET-derived metabolic tumor volume metrics predict progression-free and overall survival in DLBCL after first-line treatment: results from the phase 3 GOYA study. Blood. 2017.Google Scholar
  4. 4.
    Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large b-cell lymphoma. J Clin Oncol. 2017;35:3529–37.CrossRefGoogle Scholar
  5. 5.
    Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma. PLoS One. 2015;10:e0140830.CrossRefGoogle Scholar
  6. 6.
    Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Nuclear MedicineGuy’s and St Thomas’ NHS Foundation TrustLondonUK
  2. 2.Department of Clinical OncologyGuy’s and St Thomas’ NHS Foundation TrustLondonUK
  3. 3.KCL and Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging SciencesKings College London at St Thomas’ Hospital, Kings Health PartnersLondonUK
  4. 4.Department of Cancer Epidemiology and Population HealthKing’s College London, Kings Health PartnersLondonUK

Personalised recommendations